Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colistin vs. Colistin plus Meropenem for MDR Gram-negative infections
NCT01732250Phase 4Completed
- Start
- Mar 2013
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 4, randomised, open-label trial of meropenem in Gram-negative bacterial infection. Primary endpoint: Clinical success at 14 days. Started Mar 2013; status: completed.
02
Drugs
meropenem
03
Conditions
Gram-negative bacterial infection
Beyond the preview
Go deeper on NCT01732250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01732250.